Royalty Pharma (RPRX) Total Liabilities (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Total Liabilities data on file, last reported at $9.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 26.33% year-over-year to $9.9 billion; the trailing twelve-month figure through Mar 2026 stood at $9.9 billion (up 26.33% YoY), and the FY2025 full-year result was $9.9 billion, up 25.7% from the prior year.
• Total Liabilities steadied at $9.9 billion in Q1 2026, from $9.9 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $9.9 billion in Q4 2025 to a low of $6.3 billion in Q1 2024.
• A 5-year average of $7.8 billion and a median of $7.3 billion in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities fell 13.59% in 2023 and grew 26.33% in 2026, its largest moves.
• Tracing RPRX's Total Liabilities over 5 years: stood at $7.3 billion in 2022, then slipped by 13.59% to $6.3 billion in 2023, then increased by 25.13% to $7.9 billion in 2024, then increased by 25.7% to $9.9 billion in 2025, then decreased by 0.28% to $9.9 billion in 2026.
• Business Quant data shows RPRX's Total Liabilities at $9.9 billion in Q1 2026, $9.9 billion in Q4 2025, and $9.7 billion in Q3 2025.